Cardinal Health (NYSE: CAH) today released Q4 results that handily beat the Wall Street consensus on profits, even as it missed on revenue.
The Dublin, Ohio pharmaceutical, medtech, and healthcare distribution giant also projected an EPS range for its new fiscal year that exceeded analysts’ expectations.
CAH shares were up more than 4% to $248.60 apiece in morning trading. The S&P 500 was up slightly.
“The broad-based operational strength for the year, with all five of our operating segments growing profit double-digits, even before recognition of IEEPA tariff recoveries in GMPD, reflects the disciplined execution of our strategy and our investments for growth. We enter fiscal 2027 with momentum and confidence in our ability to deliver continued shareholder value creation,” Cardinal Health CEO Jason Hollar said in a news release.
Cardinal Health earned $398 million, or $1.70 per share, off of $63.7 billion in revenue for the quarter ended June 30, 2026. Profits were up 67%, and revenue was up 6% compared with Q4 2025.
Adjusted to exclude one-time items, Cardinal Health’s EPS was $2.91. The result was 49¢ ahead of The Street, where analysts expected EPS of $2.42 and revenue of $65.11 billion.
For the full year, Cardinal Health earned $1.7 billion, or $7.23 per share, off of $254.2 billion in revenue — with profits up 10% and revenue up 14%. The Pharmaceutical and Specialty Solutions segment saw profits grow 23% to $2.8 billion and revenue increase 15% to $234.8 billion. Global Medical Products and Distribution segment profits were up 91% to $258 million, with revenue ticking up 1% to $12.7 billion.
For the new fiscal year, Cardinal Health expects adjusted EPS of $12.40–$12.60; the Wall Street consensus had been $12.05. Pharmaceutical and Specialty Solutions segment profit and revenue is expected to grow 8–11% and 3–5% respectively. Global Medical Products and Distribution segment will have profits decrease slightly to $200–220 million, with revenue up 2–4%.
